Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Precursor B-cell Or T-cell Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma
  • Age: Between 1 - 30 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Documented Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma 2. Second or greater relapse or refractory to 2 prior induction regimens for B-ALL 3. First or greater relapse or refractory to 1 prior induction/consolidation regimen for T-ALL

You may not be eligible for this study if the following are true:

  • 1. Received an allogeneic hematopoietic transplant within 3 months 2. Active acute graft-versus-host disease 3. Received immunosuppression post hematopoietic transplant within 1 month of study entry


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.